Patents by Inventor Jane Gross

Jane Gross has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of using IL-31 antagonists in diseases mediated by cutaneous lymphocyte antigen positive T cells
    Patent number: 8926957
    Abstract: The present invention relates to predicting therapeutic response of treating patients suffering from itching and pruritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: January 6, 2015
    Assignee: ZymoGenetics, Inc.
    Inventors: Janine Bilsborough, Jane A. Gross
  • METHODS OF USE FOR TACI-IMMUNOGLOBULIN FUSION PROTEINS
    Publication number: 20140328844
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Application
    Filed: July 15, 2014
    Publication date: November 6, 2014
    Inventors: Mark W. Rixon, Jane A. Gross
  • Methods for Preparing TACI-immunoglobulin fusion proteins
    Patent number: 8815238
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Grant
    Filed: August 1, 2013
    Date of Patent: August 26, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Mark W. Rixon, Jane A. Gross
  • LEVELS OF BCMA PROTEIN EXPRESSION ON B CELLS AND USE IN DIAGNOSTIC METHODS
    Publication number: 20140220014
    Abstract: The present invention provides a method of measuring the levels of BCMA in a biological sample, specifically upon the B cell surface. The diagnostic assays are useful in predicting an individual's likelihood of developing or currently suffering from an autoimmune disease, such as SLE, and for methods for treating an individual clinically diagnosed with an autoimmune disease.
    Type: Application
    Filed: February 28, 2014
    Publication date: August 7, 2014
    Applicants: University of Washington, ZymoGenetics, Inc.
    Inventors: Stacey R. Dillon, Jane A. Gross, Keith B. Elkon
  • Methods for treating autoimmune diseases using a TACI-Ig fusion molecule
    Patent number: 8784812
    Abstract: In various embodiments, the present invention provides methods and compositions for treatment of autoimmune diseases, including rheumatoid arthritis, for example comprising administering to a patient in need of such treatment a TACI-Ig fusion molecule. In one embodiment, the TACI-Ig fusion molecule is administered in amount sufficient to slow, suppress or inhibit proliferation-inducing functions of BlyS and APRIL.
    Type: Grant
    Filed: May 15, 2007
    Date of Patent: July 22, 2014
    Assignees: Zymogenetics, Inc., Ares Trading S.A.
    Inventors: Herve Broly, Jennifer Visich, Ivan Nestorov, Sharon Busby, Jane Gross
  • Method of treating atopic dermatitis with antibody to zcytor17 ligand
    Patent number: 8778344
    Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: July 15, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Jane A. Gross, Angela K. Hammond
  • ZCYTOR17 HETERODIMERIC CYTOKINE RECEPTOR
    Publication number: 20140141485
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.
    Type: Application
    Filed: December 23, 2013
    Publication date: May 22, 2014
    Applicant: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
  • ZCYTOR17 heterodimeric cytokine receptor polynucleotides
    Patent number: 8647866
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: February 11, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
  • METHODS FOR USING TACI-IMMUNOGLOBULIN FUSION PROTEINS
    Publication number: 20130309231
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Application
    Filed: August 1, 2013
    Publication date: November 21, 2013
    Applicant: Zymogenetics, Inc.
    Inventors: Mark W. Rixon, Jane A. Gross
  • Methods of treatment using taci-immunoglobulin fusion proteins
    Patent number: 8524232
    Abstract: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
    Type: Grant
    Filed: May 11, 2011
    Date of Patent: September 3, 2013
    Assignee: Zymogenetics, Inc.
    Inventors: Mark W. Rixon, Jane A. Gross
  • USE OF ZCYTOR17 LIGAND ANTAGONISTS FOR TREATING INFLAMMATORY DISEASES
    Publication number: 20130156695
    Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Application
    Filed: January 26, 2012
    Publication date: June 20, 2013
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Jane A. Gross, Angela K. Hammond
  • Methods of using IL-31 antagonists in diseases mediated by cutaneous lymphocyte antigen positive T cells
    Patent number: 8435745
    Abstract: The present invention relates to predicting therapeutic response of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population.
    Type: Grant
    Filed: March 19, 2010
    Date of Patent: May 7, 2013
    Assignee: ZymoGenetics, Inc.
    Inventors: Janine M. Bilsborough, Jane A. Gross
  • Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
    Patent number: 8388964
    Abstract: The present invention relates to methods of treating patients suffering from itching and puritis mediated by cutaneous lymphocyte antigen positive T cell. In particular, diseases or disorders including contact dermatitis, drug induced delayed type cutaneous allergic reactions, toxic epidermal necrolysis, cutaneous T cell lymphoma, bullous pemphigoid, alopecia aereata, vitiligo, acne rosacea, prurigo nodularis, and herpes simplex virus, or combination thereof will benefit from the administration of an IL-31 antagonist. The invention also includes methods of predicting a therapeutically responsive patient population.
    Type: Grant
    Filed: April 26, 2011
    Date of Patent: March 5, 2013
    Assignees: ZymoGenetics, Inc., National Jewish Medical Research Center
    Inventors: Donald Y. M. Leung, Janine M. Bilsborough, Jane A. Gross
  • Cytokine zalpha11 ligand
    Patent number: 8383775
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: February 26, 2013
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • ZCYTOR17 HETERODIMERIC CYTOKINE RECEPTOR POLYNUCLEOTIDES
    Publication number: 20120264168
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.
    Type: Application
    Filed: February 27, 2012
    Publication date: October 18, 2012
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon
  • CYTOKINE ZALPHA11 LIGAND
    Publication number: 20120208772
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Application
    Filed: December 29, 2011
    Publication date: August 16, 2012
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • Cytokine zalpha11 ligand antibodies
    Patent number: 8227575
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: July 24, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • Murine zcytor17 ligand polynucleotides
    Patent number: 8124378
    Abstract: The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine. The polypeptides may be used within methods for stimulating the immune system, and proliferation and/or development of hematopoietic cells in vitro and in vivo. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: February 28, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Jane A. Gross, Angela K. Hammond, Rolf E. Kuestner
  • Method of use of cytokine ZALPHA11 ligand
    Patent number: 8110180
    Abstract: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller polypeptide and peptide sequences. The antibodies may include antibodies that are polyclonal, monoclonal, murine, humanized or neutralizing. Methods for producing the antibodies are also described.
    Type: Grant
    Filed: October 20, 2006
    Date of Patent: February 7, 2012
    Assignee: ZymoGenetics, Inc.
    Inventors: Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster, Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson, Stacey R. Dillon, Angela K. Hammond
  • CYTOKINE RECEPTOR ZCYTOR17 MULTIMERS
    Publication number: 20110318354
    Abstract: Novel polypeptide combinations, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor17-containing multimeric or heterodimer cytokine receptors that may be used as novel cytokine antagonists, and within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. The present invention also includes methods for producing the multimeric or heterodimeric cytokine receptor, uses therefor and antibodies thereto.
    Type: Application
    Filed: April 13, 2011
    Publication date: December 29, 2011
    Inventors: Cindy A. Sprecher, Joseph L. Kuijper, Maria M. Dasovich, Francis J. Grant, Theodore E. Whitmore, Angela K. Hammond, Julia E. Novak, Jane A. Gross, Stacey R. Dillon